BLRX
What one share of BioLineRx holds
Pharmaceutical Preparations
We are a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. Our first approved product, APHEXDA® (motixafortide), a novel peptide for the treatment of stem-cell mobilization and solid tumors, with an indication in the United States for stem cell mobilization for autologous transplantation in multiple myeloma, is being developed and commercialized by Ayrmid Pharma Ltd.
BioLineRx’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.30 |
|---|---|
| Profit | −$0.48 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.98 |
| Cash and investments | $0.72 |
| Book value | $4.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$169.26 | $0.56 | −$155.64 | — | $374.34 |
| 2017 | — | −$162.42 | $2.25 | −$139.26 | — | $301.98 |
| 2018 | — | −$126.84 | $0.96 | −$134.64 | — | $215.70 |
| 2019 | — | −$104.28 | $0.27 | −$93.18 | — | $116.94 |
| 2020 | — | −$71.22 | $0.00 | −$55.08 | — | $37.86 |
| 2021 | $0.00 | −$24.48 | $0.09 | −$21.42 | — | $57.12 |
| 2022 | $0.00 | −$19.32 | $0.10 | −$20.46 | — | $33.06 |
| 2023 | $3.00 | −$37.74 | $0.07 | −$14.16 | — | $7.32 |
| 2024 | $14.52 | −$4.62 | $0.03 | −$22.02 | — | $3.60 |
| 2025 | $0.30 | −$0.48 | $0.01 | −$1.98 | — | $4.20 |